So I've been digging through the biotech market lately and stumbled on something that actually caught me off guard. Most biotech stocks are priced like they're already curing cancer tomorrow, right? But then you find one that actually has real revenue, real patients, and a stock price that hasn't gone completely detached from reality. That's rare enough to be worth paying attention to.

Harmony Biosciences (HRMY) isn't a name everyone knows, but the company's actually doing something smart that a lot of smaller biotech players miss. Instead of trying to compete head-to-head with the pharma giants on major diseases like cancer or heart disease, they went after rare neurological disorders. Specifically narcolepsy.

Here's what makes this interesting from a biotech market perspective: Harmony got FDA approval for pitolisant (sold as Wakix) back in 2019, and it's still the only non-controlled narcolepsy treatment available. That's a pretty solid moat. Out of roughly 170,000 narcolepsy patients in the US (diagnosed and undiagnosed combined), they've already gotten about 8,000 on the drug in five years. That's actually one of the strongest launches you see in rare disease treatments.

What I find compelling is how they're positioned now. Wakix is already generating revenue and profits. They're not just a pipeline company hoping for one big breakthrough. The cash flow from Wakix is funding their research into other rare neurological conditions, which means they can actually develop their pipeline without burning through capital like most early-stage biotech companies do.

The biotech market has gotten pretty frothy over the past decade or so. Everyone's chasing the next moonshot story. But sometimes the real value is in the company that's already proven it can execute, has a real product with real demand, and isn't priced like it's going to 10x overnight. That's the angle here.

I'll be watching how their pipeline develops and whether they can replicate the Wakix success in other rare disease areas. If they can, this could be one of those biotech market stories where the stock actually makes sense at current levels instead of requiring a miracle to justify the valuation. Worth keeping on your radar if you're looking at the space.